---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-118127"
form_type: "8-K"
ticker: "LABT"
cik: "0002079272"
company_name: "Lakewood-Amedex Biotherapeutics Inc."
filed_at: "2026-11-10T22:20:52+00:00"
generated_at: "2026-11-10T22:22:05.149524+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lakewood-Amedex redeems all 127,097 Series C preferred shares for $1.27M cash

## Summary
- Redeemed 127,097 Series C Convertible Preferred shares at $10.00 face value, aggregate $1,270,970 paid in cash from cash on hand.
- Redemption agreement dated Nov 2, 2026 with Shakawe Capital LLC, holder of all Series C preferred; closing occurred Nov 4, 2026.
- Following redemption, no preferred stock and no outstanding indebtedness for borrowed money remain; redeemed shares returned to treasury.
- Company says the move eliminates potential dilution from Series C conversion and removes financing restrictions tied to the instrument.
- CEO Kelvin Cooper said the redemption simplifies the capital structure and gives greater financial flexibility for development programs.

## SEC filing metadata
- accession: 0001213900-26-118127
- form_type: 8-K
- ticker: LABT
- cik: 0002079272
- company_name: Lakewood-Amedex Biotherapeutics Inc.
- filed_at: 2026-11-10T22:20:52+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2079272/000121390026118127/0001213900-26-118127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2079272/000121390026118127/ea0311576-8k_lakewood.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-118127
- JSON: https://secwatch.observer/filing/0001213900-26-118127.json
- Plain text: https://secwatch.observer/filing/0001213900-26-118127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.